metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)
versus exemestane
	tucidinostat plus exemestane
	ACE, 2019 Lancet Oncol 2019; 20:806-815-. NCT02482753	RCT	la/mBC - HR-positive - 2nd line (L2)	tucidinostat plus exemestane	placebo plus exemestane	Postmenopausal women with HR-positive, HER2-negative, inoperable BC, whose disese relapsed after at least one endocrine therapy.	244 / 121	low	conclusif	demonstrated 25 % decrease in progression or deaths (PFS) (PE)

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

RCT

la/mBC - HR-positive - 2nd line (L2)

tucidinostat plus exemestane

placebo plus exemestane

Postmenopausal women with HR-positive, HER2-negative, inoperable BC, whose disese relapsed after at least one endocrine therapy.

244 / 121